VOMIKIND 2mgml Solution for injection

দেশ: মাল্যাশিয়া

ভাষা: ইংরেজি

সূত্র: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

সক্রিয় উপাদান:

ONDANSETRON HYDROCHLORIDE DIHYDRATE

থেকে পাওয়া:

PAHANG PHARMACY SDN. BHD.

INN (আন্তর্জাতিক নাম):

ONDANSETRON HYDROCHLORIDE DIHYDRATE

প্যাকেজ ইউনিট:

2 ml; 4 ml

Manufactured by:

Mankind Pharma Limited (Unit I)

তথ্য লিফলেট

Not Applicable

পণ্য বৈশিষ্ট্য

VOMIKIND
2MG/ML SOLUTION FOR INJECTION
Ondansetron Hydrochloride Dihydrate
PRODUCT NAME:
VOMIKIND 2MG/ML SOLUTION FOR INJECTION
NAME AND STRENGTH OF ACTIVE INGREDIENTS:
Each ml contains Ondansetron Hydrochloride USP eq. to Ondansetron 2
mg.
Each 2 ml injection ampoule contains Ondansetron 4 mg.
Each 4 ml injection ampoule contains Ondansetron 8 mg.
_NOT ALL PACK PRESENTATIONS ARE AVAILABLE IN EVERY COUNTRY_
PRODUCT DESCRIPTION:
Solution for Injection (Clear, colourless liquid)
PHARMACOLOGICAL PROPERTIES:
PHARMACOTHERAPEUTIC
GROUP:
ANTI-EMETICS
AND
ANTINAUSEANTS,
SEROTONIN
(5HT
3
)
ANTAGONIST, ATC CODE: A04AA01
PHARMACODYNAMICS PROPERTIES
Ondansetron is a potent, highly selective 5HT
3
receptor-antagonist. Its precise mode of action in
the control of nausea and vomiting is not known. Chemotherapeutic
agents and radiotherapy may
cause release of
5HT in the small
intestine initiating a vomiting reflex by activating vagal
afferents via 5HT
3
receptors. Ondansetron blocks the initiation of this reflex.
Activation of vagal
afferents may also cause a release of 5HT in the area postrema,
located on the floor of the fourth
ventricle,
and this may also promote emesis through a central
mechanism.
Thus,
the effect
of
Ondansetron in the management of the nausea and vomiting induced by
cytotoxic chemotherapy
and radiotherapy is probably due to antagonism of 5HT
3
receptors on neurons located both in the
peripheral
and central
nervous system.
The mechanisms of action in post-operative nausea and
vomiting are not known but there may be common pathways with cytotoxic
induced nausea and
vomiting.
Ondansetron does not alter plasma prolactin concentrations.
The role of Ondansetron in opiate-induced emesis is not yet
established.
PHARMACOKINETICS PROPERTIES
The pharmacokinetic properties
of
ondansetron are unchanged on repeat
dosing.
A direct
correlation of plasma concentration and anti-emetic effect has not
been established.
Absorption
Following oral
administration,
ondansetron is
passively and completely absorbed from the
gastroint